← Leaderboards
Ronald A Peck
University Of Virginia Charlottesville
$222,236
Attributed
$222,236
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$222,236 · 2
By mechanism
M01$222,236 · 2
Top collaborators
No co-investigators on record.
Most similar at University Of Virginia Charlottesville
Same institution · by research overlap
- Sidney Michael Hecht$6,822,120
- Eugene J Barrett$22,317,830
- Michael F Christman$2,808,019
- Alan D. Rogol$2,440,436
- E Clarke Haley$6,735,071
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHuman SubjectHuman Therapy EvaluationClinical Trial Phase INeoplasm /Cancer ChemotherapyDosageAntineoplasticsEnzyme InhibitorsPharmacokineticsAlkyltransferaseQuinolineCombination ChemotherapyDeoxycytidineDna TopoisomerasesDrug Screening /EvaluationHuman DataLongitudinal Human StudyNeoplasm /Cancer Invasiveness
Grant awards (8)
FARNESYL TRANSFERASE INHIBITOR R115777 COMBINED W CAPECITABINE IN INCURABLE CANCE$48,533
M01 · FY2002 · RR
PHASE I TRIAL OF SINGLE DOSE J 107088 IN PATIENTS WITH ADVANCED CANCERS$48,533
M01 · FY2002 · RR
FARNESYL TRANSFERASE INHIBITOR R115777 COMBINED W CAPECITABINE IN INCURABLE CANCE$48,533
M01 · FY2001 · RR
PHASE I TRIAL OF SINGLE DOSE J 107088 IN PATIENTS WITH ADVANCED CANCERS$48,533
M01 · FY2001 · RR
PHASE I TRIAL OF SINGLE DOSE J 107088 IN PATIENTS WITH ADVANCED CANCERS$28,104
M01 · FY2000 · RR
FARNESYL TRANSFERASE INHIBITOR R115777 COMBINED W CAPECITABINE IN INCURABLE CANCE$0
M01 · FY2000 · RR
FARNESYL TRANSFERASE INHIBITOR R115777 COMBINED W CAPECITABINE IN INCURABLE CANCE$0
M01 · FY2000 · RR
PHASE I TRIAL OF SINGLE DOSE J 107088 IN PATIENTS WITH ADVANCED CANCERS$0
M01 · FY2000 · RR